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Recent evidence in the field of tobacco research has provided new
insights about the mechanisms underlying the effects of nicotine
and its derivatives (NAD) in human and animal behavior and
pathology. This topic covers several areas of clinical and basic
research focused on the effect of NAD on brain function and
behavior during development and adulthood. As expressed by
Spijker and colleagues (Counotte et al., 2012), there is a Ying and
a Yang in the effect of nicotine and its metabolites on the brain
(Figure 1).
The influence of NAD on addictive behavior and the mech-
anisms involved are of great interest for public health. One of
our articles explores the molecular mechanisms associated with
the differences in addiction to tobacco between genders. They
investigated the effect of nicotine, cotinine, and anabaseine on
the estrogen biosynthesis in the brain. They show experimen-
tal evidence that these compounds affect estrogen synthesis in
the brain via the modulation of the last enzyme of the estrogen
biosynthesis named aromatase. Based on this evidence they dis-
cussed the hypothesis that brain aromatase mediates the effect
of nicotine in the brain resulting in sex differences in smoking
behavior. Prenatal NAD exposure may affect addictive behavior
FIGURE 1 | The Ying and Yang of the effects Nicotine and Cotinine in
the adult brain.
later in life, several studies have shown that maternal smoking
and prenatal nicotine affect brain development and motivated
behavior. In here, Harrod et al. show evidence that prenatal
nicotine exposure have reinforcing influence over the addictive
properties of methamphetamine, affecting vulnerability to addic-
tive behavior in the adulthood (Harrod et al., 2012). Similarly
Chen et al. discuss the influence of prenatal nicotine from tobacco
smoking on feeding behavior in adulthood as well as the poten-
tial of nicotine as a weight loss treatment (Chen et al., 2012).
Furthermore, other addictive behaviors such as alcohol depen-
dence may heavily influence the effect of NAD on cognitive
abilities. For example, Durazzo et al. found increased neu-
rocognitive deficits in alcohol dependent individuals that also
were smokers when compared to non-smokers (Durazzo et al.,
2012).
On the other hand, the effect of nicotine on neuroplastic-
ity is controversial, and its improvement and deterioration by
NAD have been described. In fact, the investigation by sev-
eral research groups about the effect of nicotine on atten-
tion (Kadir et al., 2006) and learning and memory have given
heterogeneous results (Smith et al., 2006). Grundey et al.
(2012) show new evidence of a negative effect of nicotine
spray on facilitatory plasticity and a diminished reduction in
excitability after transcranial direct current stimulation. These
results differ from the effects observed after chronic nico-
tine administration. They attributed these differences to the
adaptive nicotinic receptor changes induced by continue nico-
tine exposure. These heterogeneous effects can be the result
of a differential effect of NADs according to the brain state.
Counotte et al. (2012) discuss the diverse responses to nico-
tine on attention, depending on several factors including the
extent of exposure (acute vs. chronic), smoking behavior, the
developmental stage at which the brain is exposed to nicotine
and the presence of psychiatric conditions such as, schizophre-
nia and Alzheimer’s Disease (AD). Psychiatric conditions and/or
chronic nicotine exposure may also alter the expression or
responsiveness of the cholinergic receptors in the brain and
consequently the effect of nicotine on higher order cognitive
functions.
Some epidemiological studies have shown data suggesting an
inverse relationship between tobacco consumption and the devel-
opment of AD (Lee, 1994). It has also been found post-mortem
that the levels of b-amyloid peptides (Aβ) (considered the neu-
rotoxic agents in AD brains) were significantly decreased in the
brains of smoking AD patients compared to non-smokers with
the disease. The putative beneficial effect of tobacco has been
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mainly attributed to nicotine, which has been reported to improve
cognitive abilities and reduce plaques in a mouse model of AD
(Nordberg et al., 2002). However, nicotine has not demonstrated
in clinical studies to be a useful treatment for AD (Lopez-Arrieta
et al., 2001). Since nicotinic acetylcholine receptors (nAChRs)
play an important role in attention and learning and memory,
the positive effects of nicotine on memory have been mostly
credited to the activation of these receptors (Sabbagh et al.,
2002). A change in the function of nAChRs will influence the
release and activity of other neurotransmitters whose release is
controlled by these receptors including glutamate, dopamine,
serotonin, glycine, and g aminobutyric acid (GABA) (Livingstone
and Wonnacott, 2009).
Knott et al. show evidence implicating the N-methyl-d-
aspartate receptor (NMDAR) in the beneficial effect of nico-
tine over auditory, sensory, memory and attention in a human
ketaminemodel of schizophrenia (Knott et al., 2012). In addition,
it is discussed the beneficial effect of cotinine, the mainmetabolite
of nicotine, improving memory and attention in several psychi-
atric conditions including AD (Echeverria et al., 2011), post-
traumatic stress disorder (Zeitlin et al., 2012), and schizophrenia
(Buccafusco and Terry, 2009). This evidence permits to hypothe-
size that many of the beneficial effects of nicotine may be at least
in part the result of cotinine’s actions in the brain (Echeverria
and Zeitlin, 2012). The involvement of nicotine action in AD is a
complex scientific question, and still needs to be defined whether
cognitive impairment in AD is mainly induced by a decrease in
the number of nAChRs and/or their function induced by neuro-
toxic forms of Aβ. In this topic, Zappettini et al. show evidence
suggesting that Aβ1-40 inhibits the release of glycine in the hip-
pocampus throughout a mechanism involving the nAChRs but
not the muscarinic receptors (Zappettini et al., 2012).
All together this topic gives an actualized view of the NAD
effects in aspects of addictive behavior, attention, neuroplasticity,
and learning and memory under physiological and pathological
conditions.
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